Lyra therapeutics announces initiation of lyr-210 pivotal phase 3 enlighten program in surgically naÏve chronic rhinosinusitis patients

Watertown, mass., jan. 24, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, today announced the initiation of the phase 3 enlighten i clinical trial of lyr-210 in adult, surgically naÏve chronic rhinosinusitis (crs) patients, with trial sites open for enrollment.
LYRA Ratings Summary
LYRA Quant Ranking